Introduction: Trastuzumab is an HER-2 targeted humanized monoclonal antibody that significantly improves breast cancer therapeutic outcomes. However, it is associated with an increased cardiotoxicity risk that ranges…
HER2 extracellular domain (ECD). This provides ligand-independent growth to breast cancer cells and trastuzumab, anti-HER2 agent, cannot inactivate HER2 by binding ECD portion of it. In our previous ... studies, we…
higher survival rates bring more patients presenting with cardiac adverse effects. Signaling inhibitors like trastuzumab have a risk of cardiovascular adverse effects including cardiac dysfunction and development of…
Cardiotoxicity (TC) is the most concerning side effect of Trastuzumab. It remains unclear whether the current arbitrary recommendations provide an adequate balance between preventing heart damage and curtailing a…
first- line treatment for HER-2 positive Metastatic Breast Cancers is the combination of trastuzumab, pertuzumab, and taxane (PTH). ABP 980 is a biosimilar of the innovator trastuzumab ... from therapy. Biosimilar ABP…
Different published clinical studies have demonstrated the non-inferiority of trastuzumab subccutaneous (SC) administration versus intravenous (IV) in terms of efficacy, safety and preference in the treatment of…
Empirically, trastuzumab has been continued in many patients with disease progression, mainly due to its favourable safety profile and the assumption that progression was due to resistance ... administered…
Factor receptor 2 (HER2) is expressed in 6%-23% gastric cancer tissues. Administration of Trastuzumab, a fully humanized monoclonal antibody targeted to the HER2, is associated with survival rate ... vitro and in vivo…
among the leading causes of morbidity and mortality in cancer patients treated with Trastuzumab (T), Pertuzumab (P) and Trastuzumab-DM1 (TDM1) [1-3]. Sacubitril-valsartan (LCZ 696), a drug used
recognition of specific markers and application of targeted treatment like monoclonal antibodies which Trastuzumab and Tamoxifen are the most common examples. The aim of this review is describing the different
Trastuzumab is a monoclonal antibody directed against the product of the HER2/neu oncogene. The HER2 protein is overexpressed in approximately 20% of human breast cancers and is associated with ... with HER2-positive…
human breast cancers, which is associated with poor prognosis and a high recurrence rate. Trastuzumab is the first humanized monoclonal antibody against HER2. Trastuzumab-induced cardiac dysfunction ... major side…
Despite great success as a targeted breast cancer therapy, trastuzumab use may be complicated by heart failure and loss of left ventricular contractile function. Cardiovascular disease risk factors, advanced…
present study was to investigate the effects of upregulated SHP-1 expression in reversing trastuzumab resistance and migration by HER-2-positive breast cancer cells, potentially providing a new target ... trastuzumab…
breast cancers that associated with a faster rate of growth and a poorer prognosis. Trastuzumab is FDA-approved humanized monocholonal antibody that targets the extracellular domain of HER2. In present ... study we…
Background: The main toxicity of trastuzumab, is the alteration of cardiac function. The objective of this study is to examine the acute cardiotoxicity of the combination of Radiotherapy ... trastuzumab in the adjuvant…
excreted via kidney and stool leading to suboptimal imaging. Conjugation of Gd-DOTA with trastuzumab by dendrimer will create a macromolecule and specifically bind to HER2 receptor. This study aimed ... evaluate…
Background: Trastuzumab treatment is associated with cardiac dysfunction. We evaluated the incidence of cardiotoxicity during and long-term after trastuzumab treatment in an unselected early breast cancer population…
Background: Trastuzumab may induce cardio-toxicity which can be clinically identified as decreased left ventricular systolic function with or without symptoms of heart failure. Objectives: To determine the prevalence…
cell-based production systems. PlantForm Corp. has been working on a biosimilar version of trastuzumab, a therapeutic antibody that is used for treatment of breast cancers that specifically over-express ... human…
Introduction :Trastuzumab has been used as an adjunct to chemotherapy in receptor positive breast cancer patients. However it is known to cause cardiomyopathy with left ventricular systolic dysfunction in about…
Purpose: Biosimilars are available for trastuzumab globally including India. This survey was conducted across India to understand oncology practices for the use of trastuzumab innovator and biosimilars in treatment…
humanized anti-HER2 antibody, trastuzumab (Herceptin), has been widely used in the treatment of early stage and metastatic types of HER2 positive breast cancers. Resistance to trastuzumab has become ... that perform…
tipo 2 (HER2), este ayuda a controlar el metabolismo de la glándula mamaria. El Trastuzumab es un agente terapéutico de anticuerpos monoclonales que busca ser el tratamiento de primera línea ... para el cáncer de mama…
approved. Kanjinti as an immunotherapy is biosimilar to Herceptin (reference medicine) with active ingredient trastuzumab. Clinics have had difficulties since switching from reference medicine Herceptin to a biosimilar…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.